Market Cap 516.00B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 20.38
Forward PE 19.47
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 9,949,800
Avg Vol 8,747,054
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 61%
Beta 0.36
Analysts Strong Sell
Price Target $209.13

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Suite510
Suite510 Dec. 17 at 2:34 AM
$JNJ $KVUE $SPX Hairball incoming 🐈‍⬛ J&J hit with USD 40m payout over just 2 talc-cancer claims. The US pharmaceutical company has already paid over USD 5bn in compensation amid a wave of lawsuits linking its baby powder to cancer. Cheers 🥂
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:00 AM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently showing a stable trend with a last close of $209.32. The RSI of 54.78 indicates a neutral momentum, suggesting potential for upward movement. The stock is above the 30-day moving average (MA30) of 200.81 and well above the 50-day moving average (MA50) of 196.64, indicating bullish sentiment. Directional Bias: The stock is positioned between its 60-day high of 215.19 and low of 174.83, with room to move upward. The current price is closer to the high, providing a favorable risk-reward scenario. Trade Plan: - Suggested Entry: $209.32 - Stop Loss: $205.55 (approximately 1.3% below entry) - Take Profit Targets: 1. $213.32 (2% ROI) 2. $218.32 (4.3% ROI) 3. $245.32 (17.2% ROI) This plan allows for a strategic entry with a solid risk management approach. Monitor the trade closely to adjust as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Suite510
Suite510 Dec. 16 at 9:05 PM
$JNJ $KVUE In English: Bearish 🐻 when the talc news breaks use a stop loss 😂
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 8:19 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $207.50 Put · DEC 26, 2025 Exp Entry Price: $1.30 - $1.41 Exit Price Target: $2.85 Profit Margin: +119% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Dec. 16 at 7:38 PM
$JNJ $KVUE Work on you English. Stock is up 45% YTD dork. Find something else, this isn’t your thing kid.
0 · Reply
Suite510
Suite510 Dec. 16 at 7:12 PM
$JNJ $KVUE lol 😂 where’s that loser today? guess i’m right again than wrong
0 · Reply
WheelsAreRolling
WheelsAreRolling Dec. 16 at 6:14 PM
0 · Reply
anne_equity
anne_equity Dec. 16 at 4:53 PM
$JNJ SBFM TTM sales ~$37.3M with a ~$6–7M cap… tell me that’s normal 📊
0 · Reply
Quantumup
Quantumup Dec. 16 at 4:13 PM
Oppenheimer⬆️ $NKTR's PT to $115 from $98 and reiterated at an Outperform rating. LLY $REGN SNY PFE ABBV $APGE $CRVS $JNJ Oppenheimer said in its note: NKTR provided updates on topline results from the Ph2b REZOLVE-AA study evaluating rezpeg in alopecia areata. While technically the study missed the primary endpoint (mean percent SALT change at week-36) by a whisker, excluding four patients with eligibility violations suggests a nominal statistical significance for both 24mcg/kg and 18mcg/kg doses. Moreover, about 15% of patients achieved SALT ≤20, which aligns with the lower end (15-25%) of the upside scenario outlined in our preview. Last, rezpeg showed a consistent safety profile with previously reported data. Taken together, we see compelling activity for rezpeg in AA, which, to our knowledge, is the first of its kind for a biologic (Exhibits 1-3). Our PT goes to $115 from $98 by increasing our estimated PoS for rezpeg in AA to 50%.
0 · Reply
3DBuilds
3DBuilds Dec. 16 at 1:58 PM
0 · Reply
Latest News on JNJ
2 Recession-Proof Stocks to Watch in December

Dec 16, 2025, 8:05 AM EST - 16 hours ago

2 Recession-Proof Stocks to Watch in December

WMT


Final Trade: JNJ, NVO, UBER, BMY

Dec 15, 2025, 6:22 PM EST - 1 day ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER


Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 5 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations


16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 15 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 16 days ago

2 Top Dividend Stocks to Buy and Hold

BMY


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 17 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 17 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 18 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


3 Superb Dividend Stocks to Hold for the Next 20 Years

Nov 27, 2025, 6:30 AM EST - 19 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O


1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 21, 2025, 12:43 PM EST - 25 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month


Why Johnson & Johnson's Share Price Is Popping This Month

Nov 19, 2025, 12:24 PM EST - 27 days ago

Why Johnson & Johnson's Share Price Is Popping This Month


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 4 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 4 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 4 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 5 weeks ago

Johnson & Johnson: Dividends Don't Lie


Suite510
Suite510 Dec. 17 at 2:34 AM
$JNJ $KVUE $SPX Hairball incoming 🐈‍⬛ J&J hit with USD 40m payout over just 2 talc-cancer claims. The US pharmaceutical company has already paid over USD 5bn in compensation amid a wave of lawsuits linking its baby powder to cancer. Cheers 🥂
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:00 AM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently showing a stable trend with a last close of $209.32. The RSI of 54.78 indicates a neutral momentum, suggesting potential for upward movement. The stock is above the 30-day moving average (MA30) of 200.81 and well above the 50-day moving average (MA50) of 196.64, indicating bullish sentiment. Directional Bias: The stock is positioned between its 60-day high of 215.19 and low of 174.83, with room to move upward. The current price is closer to the high, providing a favorable risk-reward scenario. Trade Plan: - Suggested Entry: $209.32 - Stop Loss: $205.55 (approximately 1.3% below entry) - Take Profit Targets: 1. $213.32 (2% ROI) 2. $218.32 (4.3% ROI) 3. $245.32 (17.2% ROI) This plan allows for a strategic entry with a solid risk management approach. Monitor the trade closely to adjust as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Suite510
Suite510 Dec. 16 at 9:05 PM
$JNJ $KVUE In English: Bearish 🐻 when the talc news breaks use a stop loss 😂
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 8:19 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $207.50 Put · DEC 26, 2025 Exp Entry Price: $1.30 - $1.41 Exit Price Target: $2.85 Profit Margin: +119% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Dec. 16 at 7:38 PM
$JNJ $KVUE Work on you English. Stock is up 45% YTD dork. Find something else, this isn’t your thing kid.
0 · Reply
Suite510
Suite510 Dec. 16 at 7:12 PM
$JNJ $KVUE lol 😂 where’s that loser today? guess i’m right again than wrong
0 · Reply
WheelsAreRolling
WheelsAreRolling Dec. 16 at 6:14 PM
0 · Reply
anne_equity
anne_equity Dec. 16 at 4:53 PM
$JNJ SBFM TTM sales ~$37.3M with a ~$6–7M cap… tell me that’s normal 📊
0 · Reply
Quantumup
Quantumup Dec. 16 at 4:13 PM
Oppenheimer⬆️ $NKTR's PT to $115 from $98 and reiterated at an Outperform rating. LLY $REGN SNY PFE ABBV $APGE $CRVS $JNJ Oppenheimer said in its note: NKTR provided updates on topline results from the Ph2b REZOLVE-AA study evaluating rezpeg in alopecia areata. While technically the study missed the primary endpoint (mean percent SALT change at week-36) by a whisker, excluding four patients with eligibility violations suggests a nominal statistical significance for both 24mcg/kg and 18mcg/kg doses. Moreover, about 15% of patients achieved SALT ≤20, which aligns with the lower end (15-25%) of the upside scenario outlined in our preview. Last, rezpeg showed a consistent safety profile with previously reported data. Taken together, we see compelling activity for rezpeg in AA, which, to our knowledge, is the first of its kind for a biologic (Exhibits 1-3). Our PT goes to $115 from $98 by increasing our estimated PoS for rezpeg in AA to 50%.
0 · Reply
3DBuilds
3DBuilds Dec. 16 at 1:58 PM
0 · Reply
UIS299010
UIS299010 Dec. 16 at 1:01 PM
$TTD $VRT $JNJ $CLS Still manually filtering targets? Why not click to see our curated list of key industries!
0 · Reply
Quantumup
Quantumup Dec. 16 at 12:14 PM
Wedbush Added $TYRA to their Best Idea List while⬆️the PT to $37 from $30 and reiterating at an Outperform rating. $URGN $JNJ $BBIO $ASND SNY BMRN Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.
0 · Reply
FrankieSmilez
FrankieSmilez Dec. 16 at 11:56 AM
$PFE $NVAX $MRNA $JNJ Pfizer forecasts lower-than-expected profits for 2026
0 · Reply
shadowpawn
shadowpawn Dec. 16 at 2:16 AM
0 · Reply
FrankieSmilez
FrankieSmilez Dec. 16 at 1:36 AM
$PFE $NVAX $MRNA $JNJ Pfizer is sharing their guidance tomorrow, and I'm not really sure what to expect. Covid sales have declined, and their recent acquisitions are still getting started before they make it to market. I have a hunch it might turn into a "sell the news" scenario, regardless of whether the news is positive or negative, especially since the stock is hovering around its peak at 26.50. But if the news is bad, it could really hit the entire Covid health sector hard.
2 · Reply
stockanalysis_
stockanalysis_ Dec. 15 at 9:14 PM
S&P 500 - 1D Performance: $NVDA $AMZN $AVGO $LLY $JNJ Market Heatmap: https://stockanalysis.com/markets/heatmap/?ref=saveontrading
0 · Reply
ceinos
ceinos Dec. 15 at 8:04 PM
$JNJ 190
0 · Reply
TraderFlorida
TraderFlorida Dec. 15 at 6:39 PM
$JNJ - up $41.00 from suggested buy entry. Projected price target $217.00 area. Congrat's!
0 · Reply
Trader_Ty
Trader_Ty Dec. 15 at 5:43 PM
$JNJ monster
1 · Reply
ajmore
ajmore Dec. 15 at 5:06 PM
$PFE could, just could pfizer be on $MRK or $JNJ shopping menu! interesting activity and compliments offerings.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 15 at 4:41 PM
0 · Reply
ZacksResearch
ZacksResearch Dec. 15 at 4:06 PM
FDA greenlight just widened the runway for $JNJ 🚀 The FDA approved Akeega for expanded use into earlier-stage prostate cancer, supported by strong phase III data and a first-of-its-kind precision combo — a meaningful expansion of its treatment footprint. See why this approval matters for JNJ’s growth story 👉 https://www.zacks.com/stock/news/2804520/fda-approves-jjs-akeega-for-expanded-use-in-prostate-cancer?cid=sm-stocktwits-2-2804520-teaser-24841&ADID=SYND_STOCKTWITS_TWEET_2_2804520_TEASER_24841
0 · Reply